Half of post-menopausal women will suffer a fracture during their lifetime, mainly because of osteoporosis. Currently available medication can halve the risk of future osteoporotic fractures. Yet many at-risk women are still unidentified, and only half of all patients persist with treatment for more than a year.
Although current treatments for osteoporosis are effective, long-term adherence is often disappointing. But the management of osteoporosis is changing. New bisphosphonate formulations already offer more convenient dosing. And it is important to know about other new and emerging approaches that look set to offer a wider choice of therapy for women with post-menopausal osteoporosis.
For too long a Cinderella condition, osteoporosis has only recently been included in the GP contract as a Directed Enhanced Service. This article explains how the new FRAX tool can help practices to individualise risk assessment and target treatment to the patients most at risk.